Get Your Personalized Supplement StackSupplement Stack Quiz

Sodium EDTA

Q: Is sodium EDTA safe for long-term use?

Oral ferric sodium EDTA is generally safe for long-term use in iron deficiency. However, intravenous EDTA chelation requires medical supervision and is not typically used long-term without specific medical indication due to potential side effects.

Q: Does EDTA chelation reduce cardiovascular risk?

Evidence is mixed. Large randomized controlled trials, such as TACT2, have shown no definitive overall benefit for general populations, though some subgroup effects were suggested. Routine use for cardiovascular risk reduction is not broadly supported.

Q: Can sodium EDTA cause mineral deficiencies?

Yes, EDTA is a chelating agent and can bind to essential minerals, potentially leading to their depletion. Monitoring mineral levels and appropriate supplementation may be necessary, especially during chelation therapy.

Q: How quickly does ferric sodium EDTA improve anemia?

Significant improvements in hemoglobin levels and other iron status markers can typically be observed within weeks to a few months of consistent supplementation with ferric sodium EDTA.

Also known as: Edetate disodium, disodium EDTA, sodium ethylenediaminetetraacetate, ethylenediaminetetraacetic acid disodium salt, Sodium EDTA

Overview

Sodium EDTA, specifically disodium EDTA, is a synthetic hexadentate chelating agent widely used in various applications, including medicine, food, and industrial processes. It is not naturally occurring and functions by binding to divalent and trivalent metal ions, forming stable, water-soluble complexes that can then be excreted from the body. In the context of supplements, it is primarily utilized in chelation therapy to remove toxic metals like lead and cadmium. A specific form, ferric sodium EDTA, is incorporated into iron supplements to enhance iron bioavailability and absorption, particularly in iron-deficient populations. Its strong metal-binding capacity and water solubility are key characteristics, making it effective for both systemic chelation (often intravenously) and targeted mineral delivery (orally). Research on Sodium EDTA is moderately mature, with several randomized controlled trials and systematic reviews available, particularly concerning its role in cardiovascular chelation therapy and iron supplementation.

Benefits

Sodium EDTA offers several evidence-based benefits, primarily through its chelating properties. In the context of iron supplementation, ferric sodium EDTA significantly improves hemoglobin levels in iron-deficient individuals, including pregnant women. A longitudinal study reported an average hemoglobin increase of 2.5 g/dL (from 8.7 g/dL to 11.2 g/dL) after treatment, which is clinically meaningful for anemia management. Another randomized controlled trial (RCT) demonstrated improved iron status markers (hemoglobin, sideremia, transferrin saturation) when ferric sodium EDTA was combined with vitamin C and other micronutrients. For chelation therapy, EDTA has been shown to enhance the excretion of toxic metals such as lead, cadmium, and gadolinium, indicating its efficacy in mobilizing these harmful substances from the body. While some subgroup benefits were observed in the TACT2 trial for cardiovascular disease, overall evidence for a definitive large-scale benefit in reducing cardiovascular events remains mixed and inconclusive. The benefits for iron deficiency are well-supported by high-quality studies, with improvements typically observed over weeks to months of supplementation.

How it works

Sodium EDTA primarily functions as a chelating agent, meaning it forms stable, cage-like complexes with metal ions. Its hexadentate structure allows it to bind tightly to divalent and trivalent metal ions such as Pb^2+, Cd^2+, Fe^3+, and Ca^2+. This chelation process renders the metal ions biologically inactive and facilitates their excretion, primarily through the kidneys via urine. In cases of toxic metal overload, this mechanism reduces the bioavailability and toxicity of harmful metals. When used as ferric sodium EDTA in iron supplements, the chelation prevents iron from forming insoluble compounds in the gastrointestinal tract, thereby maintaining it in a soluble and bioavailable form. This enhances iron absorption, particularly in the presence of other absorption enhancers like vitamin C. Intravenous administration ensures systemic availability for chelation therapy, while oral forms like ferric sodium EDTA are designed for improved absorption compared to other iron salts.

Side effects

Sodium EDTA is generally safe when used appropriately, but its administration, especially intravenously, requires careful monitoring. Common side effects with oral forms, such as ferric sodium EDTA, include mild gastrointestinal discomfort. Intravenous infusions of EDTA can lead to transient hypocalcemia or hypotension. Uncommon side effects (1-5%) include allergic reactions and nephrotoxicity, particularly in individuals with pre-existing renal impairment. Rare but severe side effects (<1%) can include severe hypocalcemia and acute renal failure. Sodium EDTA can interact with other medications and supplements by chelating essential minerals, potentially reducing their absorption; therefore, monitoring and supplementation may be necessary. Caution is advised with calcium channel blockers and other calcium-modulating agents due to the risk of exacerbating hypocalcemia. Contraindications include severe renal impairment, pre-existing hypocalcemia, and known hypersensitivity to EDTA. Pregnant women can safely use ferric sodium EDTA for iron deficiency, but intravenous chelation should only be undertaken if medically indicated and under strict supervision.

Dosage

For iron supplementation, a minimum effective dose of at least 10 mg elemental iron per day, delivered as ferric sodium EDTA, is recommended to prevent deficiency. Optimal dosage ranges for treating anemia with ferric sodium EDTA are typically around 150-230 mg (as the compound) two to three times daily. For chelation therapy, intravenous doses of 500-3000 mg of EDTA have been studied, but these require strict medical supervision and vary based on the specific metal toxicity and patient condition. The maximum safe dose for EDTA is not firmly established, and high doses carry risks of hypocalcemia and renal toxicity. Oral iron supplements containing ferric sodium EDTA are often taken with vitamin C to enhance absorption. Intravenous chelation infusions are typically administered weekly. Absorption of oral forms can be influenced by gastrointestinal pH and food intake. Co-administration with vitamin C, folic acid, and other micronutrients has been shown to improve the efficacy of ferric sodium EDTA in treating anemia.

FAQs

Is sodium EDTA safe for long-term use?

Oral ferric sodium EDTA is generally safe for long-term use in iron deficiency. However, intravenous EDTA chelation requires medical supervision and is not typically used long-term without specific medical indication due to potential side effects.

Does EDTA chelation reduce cardiovascular risk?

Evidence is mixed. Large randomized controlled trials, such as TACT2, have shown no definitive overall benefit for general populations, though some subgroup effects were suggested. Routine use for cardiovascular risk reduction is not broadly supported.

Can sodium EDTA cause mineral deficiencies?

Yes, EDTA is a chelating agent and can bind to essential minerals, potentially leading to their depletion. Monitoring mineral levels and appropriate supplementation may be necessary, especially during chelation therapy.

How quickly does ferric sodium EDTA improve anemia?

Significant improvements in hemoglobin levels and other iron status markers can typically be observed within weeks to a few months of consistent supplementation with ferric sodium EDTA.

Research Sources

https://jamanetwork.com/journals/jama/fullarticle/2822472 – This is the TACT2 Trial (Lamas et al., 2024), a large randomized clinical trial investigating edetate disodium infusions for reducing cardiovascular events. While it showed some subgroup benefits, the overall results were mixed, indicating no definitive large-scale benefit for the general population. The study was well-powered and rigorously conducted, but its findings are inconclusive for broad clinical application.
https://www.scirp.org/journal/paperinformation?paperid=112838 – This longitudinal study from 2023 focused on ferric sodium EDTA in pregnant women with iron deficiency anemia. It reported a statistically significant mean hemoglobin increase of 2.5 g/dL after supplementation, demonstrating its effectiveness as an iron supplement in this vulnerable population. The study considered confounders and had an adequate sample size.
https://academic.oup.com/metallomics/article/17/5/mfaf010/8117179 – This small controlled study (Schilling et al., 2025) evaluated metal excretion after different intravenous EDTA doses. It demonstrated dose-dependent mobilization of toxic metals while maintaining normal renal function, providing mechanistic support for the safety and efficacy of chelation therapy in mobilizing toxic metals from the body.
https://pmc.ncbi.nlm.nih.gov/articles/PMC1282574/ – This systematic review (Seely et al., 2005) analyzed seven randomized controlled trials on EDTA chelation for cardiovascular disease. It found mixed results, with some small studies suggesting benefit while others did not, ultimately concluding that the overall evidence did not support the routine use of EDTA chelation for cardiovascular disease. This highlights the need for more robust research.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9145680/ – This randomized controlled trial (Giliberti et al., 2022) investigated ferric sodium EDTA combined with vitamin C, folic acid, and trace elements for anemia treatment. It demonstrated statistically significant improvements in hematological parameters, including hemoglobin and iron status markers, supporting the efficacy of combined supplementation for managing anemia.